CA2387287A1 - Methods for automatically monitoring analyte concentration using minimally invasive devices - Google Patents
Methods for automatically monitoring analyte concentration using minimally invasive devices Download PDFInfo
- Publication number
- CA2387287A1 CA2387287A1 CA002387287A CA2387287A CA2387287A1 CA 2387287 A1 CA2387287 A1 CA 2387287A1 CA 002387287 A CA002387287 A CA 002387287A CA 2387287 A CA2387287 A CA 2387287A CA 2387287 A1 CA2387287 A1 CA 2387287A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- concentration
- measurement means
- analyte concentration
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
- A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
Abstract
Methods and devices are provided for "continuously" monitoring the concentration of an analyte in a host, i.e., for automatically measuring the concentration of an analyte at two or more paints during a given time period. In the subject methods, substantially painless single use analyte concentration detection devices are employed to measure the concentration of the analyte of interest in the host, or portion thereof, e.g., interstitial fluid, where the measurements take place automatically according to a predetermined schedule.
Devices provided by the subject methods have at least two different substantially painless single use analyte concentration measurement components which are under the control of a processing means that activates the measurement components according to a predetermined schedule. Also provided are systems and kits for use in practicing the subject methods. The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose.
Devices provided by the subject methods have at least two different substantially painless single use analyte concentration measurement components which are under the control of a processing means that activates the measurement components according to a predetermined schedule. Also provided are systems and kits for use in practicing the subject methods. The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose.
Description
METHODS FOR AUTOMATICALLY MONITORING ANALYTE CONCENTRATION
USING MINIMALLY INVASIVE DEVICES
INTRODUCTION
Field of the Invention The field of this invention is analyze determination.
Back rg o 1o Analyte detection in physiological fluids, e.g., blood or blood derived products, interstitial fluid, etc., is of ever increasing importance to today's society.
Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions. Analytes of interest include glucose for 15 diabetes management, cholesterol, and the like. In response to this growing importance of analyte detection, a variety of analyte detection protocols and devices for both clinical and home use have been developed.
Historically, blood glucose and other bodily analyze measurements were invasive.
Such measurements were generally made by withdrawing a blood sample and measuring the 2o desired analyte within the blood or plasma. Blood samples were typically withdrawn by inserting a needle into a major artery or, more commonly, a vein. Such direct vascular blood sampling employed by these early methods had several limitations, including pain, hematoma and other bleeding complications, and infection. In addition, due to the vascular damage resulting from the needle puncture, sampling could not be repeated on a routine 25 basis. Finally, it was extremely difficult for patients to perform a direct vascular puncture on themselves.
A more recent technique that has been developed to overcome some of the disadvantages associated with the above protocols is to collect a blood sample by cutting or lancing the skin and the subcutaneous tissue, including the small, underlying blood vessels, 3o to produce a localized bleeding on the body surface. A lancet, knife, or other cutting device is required. The blood on the body surface is then collected into a small tube or other container. The fingertip is the most frequently used site to collect blood in this method due to the large number of small blood vessels located in the region. One method is shown in U.S.
Pat. No. 4,637,403. This sampling method also suffers from several major disadvantages, including pain and the potential for infection and other problems associated with repeated sampling for a confined area. Pain is a major disadvantage since the fingertip has a large concentration of nerve endings. Also, there is a limited body surface area from which to take these samples and measurement on a high frequency basis.
Because the above described prior art invasive techniques are painful, patients frequently avoid having blood glucose measured. For diabetics, the failure to measure blood glucose on a prescribed basis can be very dangerous. Also, the invasive techniques, which result in lancing blood vessels, create an enhanced risk for disease transmission.
to Attempts have been made to develop glucose and other analyte sensors for implantation in the human body. Advantages of such implanted sensors include the ability to provide "continuous," chronic monitoring without having to consciously sample blood at each measuring event. Despite the many potential advantages provided by implanted sensors, development of a permanently implanted or long-term, chronic implanted sensor has 15 been unsuccessful. Attempts to develop short-term implantable sensors (up to 2-3 days) have also met with very limited success. Most implantable sensors are based on measuring various products from chemical reactions between agents) located on or within the sensor and the desired analyte. Implanted glucose sensors have typically used the glucose oxidase reaction to measure the amount of glucose, as described in U.S. Pat. No.
5,108,819. Such 2o implantable glucose sensors have been intended for insertion through the epidermis and dermis to the subcutaneous tissue. An alternative location previously described for chronic sensor implant is the peritoneal cavity. Implanted sensors typically require direct or telemetered connection to a measurement instrument, usually located external the body.
All implanted sensors are faced with several major problems. First, all foreign 25 materials, including materials incorporated into a glucose sensor, produce unwanted body reactions. Such reactions include the formation of fibroNc tissue around the sensor which alters the sensor's contact with normal body fluids and analytes, such as glucose. The body's natural defense mechanism may also have a direct "poisoning" effect upon the sensor's operation by interfering with the chemical reactions required by chemical-based sensors. As 3o with any implanted object, implanted sensors may also initiate other bodily reactions including inflammation, pain, tissue necrosis, infection, and other unwanted reactions.
Implanted sensors require certain chemicals and chemical reactions to determine the level of analyte in the surrounding medium. These chemical reactions are the source of the other major problem facing any implantable sensor. Chemically-based sensors require products to be consumed and other products to be produced as part of the sensor's normal operations. Therefore, the sensors can quickly be depleted of the chemical agents required to sustain the desired chemical reactions. Secondly, by-products are given off as a result of the basic chemical reaction. These by-products often "poison'" the sensor or cause other unwanted tissue reactivity. Because of these severe limitations, implanted sensors are not practical. Finally, such implanted sensors are painful to implant and are a source of infection.
As such, while offering benefits over traditional analyte measurement devices and protocols, such as continual, automated monitoring of the analyte of interest, implantable analyte concentration measurement devices currently available are unsatisfactory for a number of reasons.
Accordingly, there is a continued interest in the development of new analyte concentration measurement protocols and devices. Of particular interest would be the development of a continuous analyte concentration measurement system that does not suffer from disadvantages experienced with implantable sensors, as reviewed above.
Relevant Literature U.S. Patents of interest include: 4,680,628; 4,721,677; 5,002,054; 5,108,819;
5,161,532; 5,390,671, 5,582,184; 5,682,233; 5,746,217; 5,820,520; 5,879,310;
6,056,738;
6,086,545; 6,091,975; and 6,155,992.
SUMMARY OF TEiE INVENTTON
Methods and devices are provided for "continuously" monitoring the concentration of an analyte in a host, i.e., for automatically measuring the concentration of an analyte in a host at two or more points over a given time period. In the subject methods, substantially painless single use analyte concentration detection devices are employed to measure the concentration of the analyte of interest in the host, or portion thereof, e.g., interstitial fluid, where the measurements takes place automatically according to a predetermined schedule.
Devices of the subject invention have at least two different substantially painless single use analyte concentration measurement components which are under the control of an activation means that activates the measurement components according to a predetermined schedule.
Also provided are systems and kits for use in practicing the subject methods.
The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Methods and devices are provided for automatically monitoring the concentration of an analyte in a host or portion thereof, i.e.., for automatically measuring the concentration of an analyte at two or more points over a given time period. In the subject methods, substantially painless single use analyte concentration detection devices are employed to measure the concentration of the analyte of interest in the host, or portion thereof, e.g., interstitial fluid, where the measurements take place automatically according to a predetermined schedule. Devices provided by the subject invention have at least two different substantially painless single use analyte concentration measurement components that are under the control of an activation means that activates the measurement components according to a schedule. Various types of measurement scheduling modes are employable with the present invention. For example, the schedule may be predetermined according to either fixed times of day or fixed interv als of time. The schedule may otherwise be "adaptive" in response to immediate or short-term (i.e., within hours) preceding data.
Another type of scheduling is one that is "predictive" in response to previous data collected over a longer period (i.e., over one or more days). The present invention may also provide an "on-demand" mode where the physician or patient may overnde the programmed measurement schedule and activate measurement of the target analyte.
Also provided are systems and kits for use in practicing the subject methods.
The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose in interstitial fluid.
Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments rnay be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting.
Instead, the scope of the present invention will be established by the appended claims.
In this specification and the appended claims, singular references include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
METHODS
As summarized above, the subject invention is directed to methods and devices for monitoring the concentration of an analyte of interest in a host or portion thereof. By monitoring is meant that the concentration of the analyte of interest is measured two or more l0 times over a given time period, such that two or more measurements of the analyte concentration are obtained for a given time period. The given period of time may vary from 1 hour to several hours, to days. However, the given period of time typically ranges from about 1 hour to 2 days, and is often 2 to 8 hours. Measuring the analyte concentration at least twice during the given time period provides for the monitoring of the analyte 15 concentration during the time period.
A feature of the subject methods is that the monitoring is automatic. In characterizing the monitoring as automatic, what is meant is that the individual analyte measurements that make up the monitoring protocol are made according to a schedule, typically under the direction of an automatic activation means, as described in greater detail infra. The 20 predetermined scheduling modes can provide exact points in time at which measurements are to be made.
For predetermined "fixed interval" or periodic scheduling modes, a plurality of measurements are made during a given period of time when practicing the subject methods.
While the number of measurements that are made in a given period of time necessarily 25 varies at least in part with respect to the particular time period, the time interval or duration between measurements is the same. For example, where the period of time for collecting measurements is 8 hours, the number of measurements that are made is at least 4, usually at least 8 and more usually at least 16, where the number may be substantially higher, e.g., 24, 36, 48, or higher, depending on the desired frequency of analyte concentration measurement 30 for the 8 hour period. Therefore, in a given period of time, individual analyte concentration measurements may be made every 5 minutes, every ten minutes, every .5 hours, every hour, every 2 hours, every 4 hours, etc. For example, if measurements are to be made every ten minutes during an 8 hour time period, the predetermined schedule employed in the subject method would provide for measurements to be taken at t=10 minutes, t=20 minutes, t=30 minutes, t=40 minutes, t=50 minutes and t=60 minutes, etc., as measured from t=0, representing the start of testing. The particular periodicity of~ analyte concentration measurements that are made during a given time period when practicing the subject methods is not critical, so long as at least two measurements are made during the time period such that the analyte concentration is monitored, and not just measured once.
For predetermined "fixed time" scheduling modes, a plurality of measurements are also made during a given period of time when practicing the subject methods.
However, the interval at which the measurements are conducted are not fixed but are pre-selected for 1o certain times of the day or night, such as 8 am, 9 am, 10:30 am and 11 am.
This predetermined schedule can be programmed into the activation means by either the patient or the healthcare provider.
In other scheduling modes, the activation by which the measurement means is initiated can be based on data previously obtained within a certain period.
This type of scheduling mode may be adaptive or predictive. In an adaptive mode, measurements are activated based on data received or collected in the recent past, such as within the last 0.5 to 12 hours, for example. In a predictive mode, measurements are activated based on data received or collected over a greater period of time such as within the last day or two. Such types of scheduling modes may be adjunct to a predetermined scheduling mode wherein the 2o adaptive or predictive mode is activated based on previous measurement criteria which may be out of a certain specified range, e.g., one that indicates a rise or fall in the analyte concentration. For example, with diabetic patients, an adaptive mode may be activated where several of the more recent analyte measurements indicate that the change in glucose concentration level is too rapid. With such patients, a predictive mode may be activated if previous measurements indicate a swing in glucose levels during, for example, the early morning hours over the last few days. The new scheduling patterns invoked by the adaptive or predictive modes may themselves be predetermined with either fixed, partially fixed or unfixed measurement intervals. For example, in the case of the diabetic who has recently experienced a sharp rise or fall in his glucose concentration level which has triggered an 3o adaptive measurement scheduling mode, a 5 minute-interval measurement schedule may be invoked to closely monitor the glucose level if the situation warrants additional measures, e.g., an immediate intake of glucose. In the situation where changes in glucose levels generally occur during a certain time of day and, thus, activate a predictive scheduling mode, measurements may then be scheduled at 0.5 hour-intervals during the hours from 5 am to 9 am, for example, and then revert to a more typical measurement schedule during the rest of the day.
The present invention also provides for the optional feature of scheduling "on-demand" in which the patient or healthcare provider manually overrides the current scheduling mode and immediately activates the measurement means. For example, a diabetic patient may desire to know his or her current glucose level before and/or after eating a food having high sugar content. Upon an office visit b,y a patient, a physician may want to know the patient's current glucose level.
1o Another feature of the subject methods is that each analyte concentration measurement made during a given monitoring protocol is made with a substantially painless single use analyte concentration measurement means. By "single-use" is meant that the analyte concentration means is one that is used only once, and then not used again for analyte concentration measurement. As such, the analyte concentration measurement means employed in the subject invention are distinguished from the measurement means found in conventional implantable sensors in that the conventional implantable sensors are not single-use, i.e., they are used a plurality of times. The analyte concentration measurement means employed in the subject methods are preferably ones that are precalibrated, i.e., do not need to be adjusted prior to taking the anlayte measurement. By substantially painless it is meant that the analyte concentration means of the subject invention causes the host to experience little or no pain at any time during its use, e.g., during activation or measurement, such as insertion, sampling and withdrawal, while awake and during sleep.
As indicated above, the analyte concentration is monitored in the subject methods in a host or portion thereof. Typically the analyte concentration is measured in a portion of a host, e.g., a biological fluid from a host. Biological fluids of interest include blood and fractions thereof, e.g., serum, plasma, etc., interstitial fluidand the like.
In certain embodiments, the concentration of the analyte is measured in host biological fluid, where the observed measurement is then used to derive the concentration of the analyte in another portion of the host. For example, in certain embodiments the analyte concentration is measured in host interstitial fluid, where the measured value is then used to derive the value of the analyte in the host blood.
Because a feature of the subject methods is the use of substantially painless single use analyte concentration measurement devices, the biological fluid that is measured in many embodiments is interstitial fluid. Typically, the interstitial fluid (ISF) is obtained from skin, where the ISF may be obtained from any convenient portions) of the skin, e.g., the epidermal layer, dermal layer, subdermal layer, etc.
A variety of ISF analyte measurement means, i.e., measurement means for measuring an analyte in ISF fluid, have been developed and disclosed in the prior art, where these measurement means may be readily adapted for use in the present invention.
These measurement means vary greatly in terms of configuration, nature of analyte detection and measurement, e.g., optical based, electrochemical etc., and the like.
Representative measurement means of interest include, but are not limited to, those means disclosed in U.S.
to Patent Nos. 5,746,217; 6,083,196; 5,591,139; 6,091,975 and the like, the disclosures of which are herein incorporated by reference.
In many embodiments, the measurement means will include a microneedle or analogous structure that is capable of being inserted into the skin in a substantially painless manner to sample ISF and measure the concentration of analyte in the resultant sampled/accessed ISF. Such microneedle measurement. means are disclosed in the patents listed above and incorporated herein by reference. The measurement means may be designed to measure the analyte concentration in situ or ex vivo. As such, the measurement means may measure the concentration of the analyte without withdrawing the sample from the body, or may withdraw the sample from the body and then measure the analyte 2o concentration in the withdrawn sample.
A variety of different analytes may be monitored using the subject methods, but the subject invention is particularly useful where the analyte of interest is glucose, because of the consequences of hypo- and hyperglycemia, if undetected over long periods.
In practicing the subject methods of monitoring analyte concentration in a host or portion thereof, two or more analyte concentration measurements are made during a given time period using separate or previously unused single use substantially painless analyte concentration measurement means, as described above, for each distinct or disparate measurement. The resultant measurements are then employed as a set as desired, depending on the particular application in which the subject monitoring step is being used, where 3o representative applications are described in greater detail infra. The set of measured analyte concentrations may be used in raw form, or processed as desired, e.g., fit to a curve, etc., depending on the particular application in which the monitoring finds use. In this way, the analyte concentration is monitored in a host, or portion thereof, e.g., interstitial fluid.
DEVICES AND SYSTEMS
Also provided are devices and systems for use in practicing the subject methods, as described above. The devices and systems of the subject invention include at least a first and second single use substantially painless analyte measurement means, as described above. As indicated above, the analyte measurements means of the subject devices may vary, depending on the particular region or portion of the host, the nature of the sample, the nature of the analyte, etc., where the measurement means may employ optical measurement, electrochemical measurement, or other specific measurement means. In many embodiments, the measurement means of the subject devices are ISF analyte concentration measurement means, as reviewed above.
While the device and systems of the subject invention include at least a first and second analyte measurement means, they typically include more than two measurement means, where the number of measurement means may be 4, 8, 16, 24 or higher, depending on the particular nature of the device.
In certain embodiments, the measurement means may be present on a cartridge or analogous means that can be separated or removed from the remainder of the device, such that when all of the measurement means of a given cartridge are employed, the cartridge may be removed and replaced with another cartridge, such that the whole device need not be discarded. In yet other embodiments, the measurement means may be integral and non-removable from the remainder of the device, such that when the last of the measurement means is employed, the device is discarded. Because of the lower cost and efficiency of resource use provided by the cartridge embodiments of the device, embodiments that include a removable cartridge that provides for the measurement means are preferred in many embodiments.
In addition to the measurement means, the subject devices and systems also include a measurement activation means. The measurement activation means is a means capable of activating each of the measurement means of the device according to a predetermined or pre-set schedule. Typically, the activation means is made up of suitable hardware and software components, e.g., a microprocessor under the control of a suitable algorithm, that provide for selective activation of each of the measurement means according to the desired predetermined schedule. In other words, the various components that make up the activation means are capable of activating each of the measurement means according to the measurement scheduling mode that controls the activation means. Typically, the activation means includes an algorithm that provides the instructions to the hardware component of the activation means for activating each of the measurement means according to the selected scheduling mode. The particular nature of the activation means is not critical to the device, so long as it is capable of providing for activation of the measurement means according to the desired predetermined schedule. The activation means may be readily generated from currently known and available components without undue experimentation on the part of one ordinarily skilled in the art.
The activation means that is present in the device may be a "learning"
activation means, in that it may be able to automatically modify a predetermined activation schedule according to which it activates the individual measurement means, where the modification of the schedule is based on previous analyte concentration measurements and trends thereof, e.g., patterns of analyte concentration observed by the activation means. For example, where the analyte is glucose and initial measurements made according to the predetermined t5 schedule indicate a rapid decrease in glucose concentration that warrant an increase in the measurement frequency, the activation means may be programmed to recognize such a pattern and change or adapt the activation frequency accordingly.
In addition to the activation means that automatically activate each individual measurement means of the device, the device may also include a means for manually activating a measurement means on command. For example, the device may include a button, lever or analogous means that can be manipulated at will to provide for an instant measurement of analyte concentration "on-demand".
The device may also include a processing means far collecting the raw analyte concentration measurement data from the measurement means and processing it as needed/desired into a final desired format. As such, the processing means may include date processing algorithms that convert the data into a desired format, e.g., into linear functions, etc., that correlate the data to analyte concentration of another portion of the host, e.g., that convert ISF concentration into the blood concentration; and the like.
In addition, the devices may have a readout means that displays the monitored analyte concentration. Any convenient readout or display means may be employed, including an LCD, etc, where the display means may display the data in any convenient format, e.g., numerically, graphically, etc.
The device and systems may take a variety of different configurations. In certain embodiments, the devices are single, integral devices, in which the measurement means, processing means, display means etc. are all present on the same structure. In yet other embodiments, one or more of the components may be separate from the other components.
s For example, the measurement means may be separated from the display means, where telemetric communication or analysis data transmission means, e.g., radio frequency or RF
means, are employed to provide for data communication between the two or more disparate components of the device.
One representative device embodiment is a "watch" embodiment, in which the device to is configured to be worn around a limbic portion, e.g., a wrist, in a manner analogous to a watch. In this embodiment, all of the components of the device may be present in one integral unit, where the unit is maintained in contact with the skin of the host via an adjustable strap or other retention means. Where the device is to contact a portion of the host that is not readily viewable, e.g., a portion of the waste or other portion that is typically 15 covered by clothes or otherwise not readily viewable, the two component device may be employed, where the measurement means, e.g., sample pads and sensors, are one component of the device and the display or readout means is present on the other component of the device. The two disparate components communicate with each other a data communication means, where the data communication means is typically a wireless data communication 2o means, e.g., RF telemetric means.
UTB.TTY
The subject methods, devices and systems find use in a variety of different applications in which monitoring the concentration of an analyte in a body sample over a 25 given period of time is desired. As such, the subject methods may be employed to: (a) continuously or periodically monitor an analyte whose concentration is associated with a disease condition, e.g., hypo-or hyperglycemia in blood sugar disorders such as diabetes; (b) continuously or periodically monitor an analyte whose concentration is associated with a non-disease physiological condition of interest, e.g., alcohol intoxication, illegal drug use;
30 (c) continuously or periodically monitor the concentration of a therapeutic agent in drug therapy applications; etc.
Where the analyte is glucose, the subject methods find use in a variety of different applications relating to the treatment and management of glucose-associated disease conditions, e.g., diabetes and related conditions. In these embodiments, the subject methods and devices find use in providing for "continual" glucose monitoring, by which is meant that glucose levels in a patient are measured intermittently and automatically according to a predetermined schedule. The subject methods therefore find use in the management of glucose blood levels in glucose metabolism associated disease conditions, by providing for a means to continually monitor the concentration of blood glucose and intervene in an appropriate manner where necessary, e.g., by administration of insulin, by ingestion of sugar, and the like. The subject methods can also be employed to detect and predict the occurrence of hypo- and hyperglycemic conditions. In such applications, the pattern of !o continually monitored analyte concentration measurements can be employed to determine whether a patient is experiencing hyper or hypo glycemia by comparing the pattern to a control or reference pattern. In addition, one can look at a pattern of measurements and compare it to an appropriate control or reference pattern to predict the occurrence of a hypo or hyperglycemic condition. The subject methods can be part of a more comprehensive therapy protocol designed to prevent the occurrence of hypo and hyperglycemic events, e.g., by predicting the occurrence of such events with the subject methods and device and intervening in blood sugar metabolism in a manner that prevents the occurrence of the predicted event, e.g., via insulin injection or glucose ingestion.
The subject methods and devices find use with a variety of different types of hosts 2o where analyte monitoring is desired. Hosts of interest include, but are not limited to mammals. Mammals of interest include valuable livestock, e.g., horses, cows, sheeps, etc., pets, e.g., dogs, cats etc., and humans. In most embodiments, the mammals on which the subject methods are practiced are humans.
KITS
Also provided are kits for practicing the subject methods. In one embodiment, the kits include a device for practicing the subject invention. The device may be a single integral device or made up of two or more disparate components, e.g., a display component and a measurement component. In certain embodiments, the device may be a device in which the 3o measurement means are present on a removable cartridge. In such embodiments, the kits may include a single cartridge, or two or more cartridges. In yet other embodiments, the subject kits may include one or more cartridges for use in a disparate device not included in the kit. Finally, the kits typically include instructions for using the subject reagent test strips in the determination of an analyte concentration in a physiological sample.
These instructions may be present on one or more of the packaging, a label insert, containers present in the kits, and the like.
s The subject methods and devices provide continual measurement of an analyte of interest without the problems experienced with implantable analyte sensors.
For example, because single-use substantially painless analyte measurement means are employed, user irritation and pain are avoided. Furthermore, the individual measurement means employed need not be calibrated prior to use. In addition, with respect to the glucose the subject devices and methods can not only be employed to rapidly and accurately detect the occurrence of a hypo or hyperglycemic event with out host participation, but they can also be employed to readily predict the occurrence of hypo and hyperglycemic conditions, and therefore provide for improved management of blood glucose metabolism associated disease conditions. As such, the subject invention represents a significant contribution to the art.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
USING MINIMALLY INVASIVE DEVICES
INTRODUCTION
Field of the Invention The field of this invention is analyze determination.
Back rg o 1o Analyte detection in physiological fluids, e.g., blood or blood derived products, interstitial fluid, etc., is of ever increasing importance to today's society.
Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions. Analytes of interest include glucose for 15 diabetes management, cholesterol, and the like. In response to this growing importance of analyte detection, a variety of analyte detection protocols and devices for both clinical and home use have been developed.
Historically, blood glucose and other bodily analyze measurements were invasive.
Such measurements were generally made by withdrawing a blood sample and measuring the 2o desired analyte within the blood or plasma. Blood samples were typically withdrawn by inserting a needle into a major artery or, more commonly, a vein. Such direct vascular blood sampling employed by these early methods had several limitations, including pain, hematoma and other bleeding complications, and infection. In addition, due to the vascular damage resulting from the needle puncture, sampling could not be repeated on a routine 25 basis. Finally, it was extremely difficult for patients to perform a direct vascular puncture on themselves.
A more recent technique that has been developed to overcome some of the disadvantages associated with the above protocols is to collect a blood sample by cutting or lancing the skin and the subcutaneous tissue, including the small, underlying blood vessels, 3o to produce a localized bleeding on the body surface. A lancet, knife, or other cutting device is required. The blood on the body surface is then collected into a small tube or other container. The fingertip is the most frequently used site to collect blood in this method due to the large number of small blood vessels located in the region. One method is shown in U.S.
Pat. No. 4,637,403. This sampling method also suffers from several major disadvantages, including pain and the potential for infection and other problems associated with repeated sampling for a confined area. Pain is a major disadvantage since the fingertip has a large concentration of nerve endings. Also, there is a limited body surface area from which to take these samples and measurement on a high frequency basis.
Because the above described prior art invasive techniques are painful, patients frequently avoid having blood glucose measured. For diabetics, the failure to measure blood glucose on a prescribed basis can be very dangerous. Also, the invasive techniques, which result in lancing blood vessels, create an enhanced risk for disease transmission.
to Attempts have been made to develop glucose and other analyte sensors for implantation in the human body. Advantages of such implanted sensors include the ability to provide "continuous," chronic monitoring without having to consciously sample blood at each measuring event. Despite the many potential advantages provided by implanted sensors, development of a permanently implanted or long-term, chronic implanted sensor has 15 been unsuccessful. Attempts to develop short-term implantable sensors (up to 2-3 days) have also met with very limited success. Most implantable sensors are based on measuring various products from chemical reactions between agents) located on or within the sensor and the desired analyte. Implanted glucose sensors have typically used the glucose oxidase reaction to measure the amount of glucose, as described in U.S. Pat. No.
5,108,819. Such 2o implantable glucose sensors have been intended for insertion through the epidermis and dermis to the subcutaneous tissue. An alternative location previously described for chronic sensor implant is the peritoneal cavity. Implanted sensors typically require direct or telemetered connection to a measurement instrument, usually located external the body.
All implanted sensors are faced with several major problems. First, all foreign 25 materials, including materials incorporated into a glucose sensor, produce unwanted body reactions. Such reactions include the formation of fibroNc tissue around the sensor which alters the sensor's contact with normal body fluids and analytes, such as glucose. The body's natural defense mechanism may also have a direct "poisoning" effect upon the sensor's operation by interfering with the chemical reactions required by chemical-based sensors. As 3o with any implanted object, implanted sensors may also initiate other bodily reactions including inflammation, pain, tissue necrosis, infection, and other unwanted reactions.
Implanted sensors require certain chemicals and chemical reactions to determine the level of analyte in the surrounding medium. These chemical reactions are the source of the other major problem facing any implantable sensor. Chemically-based sensors require products to be consumed and other products to be produced as part of the sensor's normal operations. Therefore, the sensors can quickly be depleted of the chemical agents required to sustain the desired chemical reactions. Secondly, by-products are given off as a result of the basic chemical reaction. These by-products often "poison'" the sensor or cause other unwanted tissue reactivity. Because of these severe limitations, implanted sensors are not practical. Finally, such implanted sensors are painful to implant and are a source of infection.
As such, while offering benefits over traditional analyte measurement devices and protocols, such as continual, automated monitoring of the analyte of interest, implantable analyte concentration measurement devices currently available are unsatisfactory for a number of reasons.
Accordingly, there is a continued interest in the development of new analyte concentration measurement protocols and devices. Of particular interest would be the development of a continuous analyte concentration measurement system that does not suffer from disadvantages experienced with implantable sensors, as reviewed above.
Relevant Literature U.S. Patents of interest include: 4,680,628; 4,721,677; 5,002,054; 5,108,819;
5,161,532; 5,390,671, 5,582,184; 5,682,233; 5,746,217; 5,820,520; 5,879,310;
6,056,738;
6,086,545; 6,091,975; and 6,155,992.
SUMMARY OF TEiE INVENTTON
Methods and devices are provided for "continuously" monitoring the concentration of an analyte in a host, i.e., for automatically measuring the concentration of an analyte in a host at two or more points over a given time period. In the subject methods, substantially painless single use analyte concentration detection devices are employed to measure the concentration of the analyte of interest in the host, or portion thereof, e.g., interstitial fluid, where the measurements takes place automatically according to a predetermined schedule.
Devices of the subject invention have at least two different substantially painless single use analyte concentration measurement components which are under the control of an activation means that activates the measurement components according to a predetermined schedule.
Also provided are systems and kits for use in practicing the subject methods.
The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Methods and devices are provided for automatically monitoring the concentration of an analyte in a host or portion thereof, i.e.., for automatically measuring the concentration of an analyte at two or more points over a given time period. In the subject methods, substantially painless single use analyte concentration detection devices are employed to measure the concentration of the analyte of interest in the host, or portion thereof, e.g., interstitial fluid, where the measurements take place automatically according to a predetermined schedule. Devices provided by the subject invention have at least two different substantially painless single use analyte concentration measurement components that are under the control of an activation means that activates the measurement components according to a schedule. Various types of measurement scheduling modes are employable with the present invention. For example, the schedule may be predetermined according to either fixed times of day or fixed interv als of time. The schedule may otherwise be "adaptive" in response to immediate or short-term (i.e., within hours) preceding data.
Another type of scheduling is one that is "predictive" in response to previous data collected over a longer period (i.e., over one or more days). The present invention may also provide an "on-demand" mode where the physician or patient may overnde the programmed measurement schedule and activate measurement of the target analyte.
Also provided are systems and kits for use in practicing the subject methods.
The subject methods find use in monitoring the concentration of a variety of different analytes of interest, and are particularly suited for use in monitoring the concentration of glucose in interstitial fluid.
Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments rnay be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting.
Instead, the scope of the present invention will be established by the appended claims.
In this specification and the appended claims, singular references include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
METHODS
As summarized above, the subject invention is directed to methods and devices for monitoring the concentration of an analyte of interest in a host or portion thereof. By monitoring is meant that the concentration of the analyte of interest is measured two or more l0 times over a given time period, such that two or more measurements of the analyte concentration are obtained for a given time period. The given period of time may vary from 1 hour to several hours, to days. However, the given period of time typically ranges from about 1 hour to 2 days, and is often 2 to 8 hours. Measuring the analyte concentration at least twice during the given time period provides for the monitoring of the analyte 15 concentration during the time period.
A feature of the subject methods is that the monitoring is automatic. In characterizing the monitoring as automatic, what is meant is that the individual analyte measurements that make up the monitoring protocol are made according to a schedule, typically under the direction of an automatic activation means, as described in greater detail infra. The 20 predetermined scheduling modes can provide exact points in time at which measurements are to be made.
For predetermined "fixed interval" or periodic scheduling modes, a plurality of measurements are made during a given period of time when practicing the subject methods.
While the number of measurements that are made in a given period of time necessarily 25 varies at least in part with respect to the particular time period, the time interval or duration between measurements is the same. For example, where the period of time for collecting measurements is 8 hours, the number of measurements that are made is at least 4, usually at least 8 and more usually at least 16, where the number may be substantially higher, e.g., 24, 36, 48, or higher, depending on the desired frequency of analyte concentration measurement 30 for the 8 hour period. Therefore, in a given period of time, individual analyte concentration measurements may be made every 5 minutes, every ten minutes, every .5 hours, every hour, every 2 hours, every 4 hours, etc. For example, if measurements are to be made every ten minutes during an 8 hour time period, the predetermined schedule employed in the subject method would provide for measurements to be taken at t=10 minutes, t=20 minutes, t=30 minutes, t=40 minutes, t=50 minutes and t=60 minutes, etc., as measured from t=0, representing the start of testing. The particular periodicity of~ analyte concentration measurements that are made during a given time period when practicing the subject methods is not critical, so long as at least two measurements are made during the time period such that the analyte concentration is monitored, and not just measured once.
For predetermined "fixed time" scheduling modes, a plurality of measurements are also made during a given period of time when practicing the subject methods.
However, the interval at which the measurements are conducted are not fixed but are pre-selected for 1o certain times of the day or night, such as 8 am, 9 am, 10:30 am and 11 am.
This predetermined schedule can be programmed into the activation means by either the patient or the healthcare provider.
In other scheduling modes, the activation by which the measurement means is initiated can be based on data previously obtained within a certain period.
This type of scheduling mode may be adaptive or predictive. In an adaptive mode, measurements are activated based on data received or collected in the recent past, such as within the last 0.5 to 12 hours, for example. In a predictive mode, measurements are activated based on data received or collected over a greater period of time such as within the last day or two. Such types of scheduling modes may be adjunct to a predetermined scheduling mode wherein the 2o adaptive or predictive mode is activated based on previous measurement criteria which may be out of a certain specified range, e.g., one that indicates a rise or fall in the analyte concentration. For example, with diabetic patients, an adaptive mode may be activated where several of the more recent analyte measurements indicate that the change in glucose concentration level is too rapid. With such patients, a predictive mode may be activated if previous measurements indicate a swing in glucose levels during, for example, the early morning hours over the last few days. The new scheduling patterns invoked by the adaptive or predictive modes may themselves be predetermined with either fixed, partially fixed or unfixed measurement intervals. For example, in the case of the diabetic who has recently experienced a sharp rise or fall in his glucose concentration level which has triggered an 3o adaptive measurement scheduling mode, a 5 minute-interval measurement schedule may be invoked to closely monitor the glucose level if the situation warrants additional measures, e.g., an immediate intake of glucose. In the situation where changes in glucose levels generally occur during a certain time of day and, thus, activate a predictive scheduling mode, measurements may then be scheduled at 0.5 hour-intervals during the hours from 5 am to 9 am, for example, and then revert to a more typical measurement schedule during the rest of the day.
The present invention also provides for the optional feature of scheduling "on-demand" in which the patient or healthcare provider manually overrides the current scheduling mode and immediately activates the measurement means. For example, a diabetic patient may desire to know his or her current glucose level before and/or after eating a food having high sugar content. Upon an office visit b,y a patient, a physician may want to know the patient's current glucose level.
1o Another feature of the subject methods is that each analyte concentration measurement made during a given monitoring protocol is made with a substantially painless single use analyte concentration measurement means. By "single-use" is meant that the analyte concentration means is one that is used only once, and then not used again for analyte concentration measurement. As such, the analyte concentration measurement means employed in the subject invention are distinguished from the measurement means found in conventional implantable sensors in that the conventional implantable sensors are not single-use, i.e., they are used a plurality of times. The analyte concentration measurement means employed in the subject methods are preferably ones that are precalibrated, i.e., do not need to be adjusted prior to taking the anlayte measurement. By substantially painless it is meant that the analyte concentration means of the subject invention causes the host to experience little or no pain at any time during its use, e.g., during activation or measurement, such as insertion, sampling and withdrawal, while awake and during sleep.
As indicated above, the analyte concentration is monitored in the subject methods in a host or portion thereof. Typically the analyte concentration is measured in a portion of a host, e.g., a biological fluid from a host. Biological fluids of interest include blood and fractions thereof, e.g., serum, plasma, etc., interstitial fluidand the like.
In certain embodiments, the concentration of the analyte is measured in host biological fluid, where the observed measurement is then used to derive the concentration of the analyte in another portion of the host. For example, in certain embodiments the analyte concentration is measured in host interstitial fluid, where the measured value is then used to derive the value of the analyte in the host blood.
Because a feature of the subject methods is the use of substantially painless single use analyte concentration measurement devices, the biological fluid that is measured in many embodiments is interstitial fluid. Typically, the interstitial fluid (ISF) is obtained from skin, where the ISF may be obtained from any convenient portions) of the skin, e.g., the epidermal layer, dermal layer, subdermal layer, etc.
A variety of ISF analyte measurement means, i.e., measurement means for measuring an analyte in ISF fluid, have been developed and disclosed in the prior art, where these measurement means may be readily adapted for use in the present invention.
These measurement means vary greatly in terms of configuration, nature of analyte detection and measurement, e.g., optical based, electrochemical etc., and the like.
Representative measurement means of interest include, but are not limited to, those means disclosed in U.S.
to Patent Nos. 5,746,217; 6,083,196; 5,591,139; 6,091,975 and the like, the disclosures of which are herein incorporated by reference.
In many embodiments, the measurement means will include a microneedle or analogous structure that is capable of being inserted into the skin in a substantially painless manner to sample ISF and measure the concentration of analyte in the resultant sampled/accessed ISF. Such microneedle measurement. means are disclosed in the patents listed above and incorporated herein by reference. The measurement means may be designed to measure the analyte concentration in situ or ex vivo. As such, the measurement means may measure the concentration of the analyte without withdrawing the sample from the body, or may withdraw the sample from the body and then measure the analyte 2o concentration in the withdrawn sample.
A variety of different analytes may be monitored using the subject methods, but the subject invention is particularly useful where the analyte of interest is glucose, because of the consequences of hypo- and hyperglycemia, if undetected over long periods.
In practicing the subject methods of monitoring analyte concentration in a host or portion thereof, two or more analyte concentration measurements are made during a given time period using separate or previously unused single use substantially painless analyte concentration measurement means, as described above, for each distinct or disparate measurement. The resultant measurements are then employed as a set as desired, depending on the particular application in which the subject monitoring step is being used, where 3o representative applications are described in greater detail infra. The set of measured analyte concentrations may be used in raw form, or processed as desired, e.g., fit to a curve, etc., depending on the particular application in which the monitoring finds use. In this way, the analyte concentration is monitored in a host, or portion thereof, e.g., interstitial fluid.
DEVICES AND SYSTEMS
Also provided are devices and systems for use in practicing the subject methods, as described above. The devices and systems of the subject invention include at least a first and second single use substantially painless analyte measurement means, as described above. As indicated above, the analyte measurements means of the subject devices may vary, depending on the particular region or portion of the host, the nature of the sample, the nature of the analyte, etc., where the measurement means may employ optical measurement, electrochemical measurement, or other specific measurement means. In many embodiments, the measurement means of the subject devices are ISF analyte concentration measurement means, as reviewed above.
While the device and systems of the subject invention include at least a first and second analyte measurement means, they typically include more than two measurement means, where the number of measurement means may be 4, 8, 16, 24 or higher, depending on the particular nature of the device.
In certain embodiments, the measurement means may be present on a cartridge or analogous means that can be separated or removed from the remainder of the device, such that when all of the measurement means of a given cartridge are employed, the cartridge may be removed and replaced with another cartridge, such that the whole device need not be discarded. In yet other embodiments, the measurement means may be integral and non-removable from the remainder of the device, such that when the last of the measurement means is employed, the device is discarded. Because of the lower cost and efficiency of resource use provided by the cartridge embodiments of the device, embodiments that include a removable cartridge that provides for the measurement means are preferred in many embodiments.
In addition to the measurement means, the subject devices and systems also include a measurement activation means. The measurement activation means is a means capable of activating each of the measurement means of the device according to a predetermined or pre-set schedule. Typically, the activation means is made up of suitable hardware and software components, e.g., a microprocessor under the control of a suitable algorithm, that provide for selective activation of each of the measurement means according to the desired predetermined schedule. In other words, the various components that make up the activation means are capable of activating each of the measurement means according to the measurement scheduling mode that controls the activation means. Typically, the activation means includes an algorithm that provides the instructions to the hardware component of the activation means for activating each of the measurement means according to the selected scheduling mode. The particular nature of the activation means is not critical to the device, so long as it is capable of providing for activation of the measurement means according to the desired predetermined schedule. The activation means may be readily generated from currently known and available components without undue experimentation on the part of one ordinarily skilled in the art.
The activation means that is present in the device may be a "learning"
activation means, in that it may be able to automatically modify a predetermined activation schedule according to which it activates the individual measurement means, where the modification of the schedule is based on previous analyte concentration measurements and trends thereof, e.g., patterns of analyte concentration observed by the activation means. For example, where the analyte is glucose and initial measurements made according to the predetermined t5 schedule indicate a rapid decrease in glucose concentration that warrant an increase in the measurement frequency, the activation means may be programmed to recognize such a pattern and change or adapt the activation frequency accordingly.
In addition to the activation means that automatically activate each individual measurement means of the device, the device may also include a means for manually activating a measurement means on command. For example, the device may include a button, lever or analogous means that can be manipulated at will to provide for an instant measurement of analyte concentration "on-demand".
The device may also include a processing means far collecting the raw analyte concentration measurement data from the measurement means and processing it as needed/desired into a final desired format. As such, the processing means may include date processing algorithms that convert the data into a desired format, e.g., into linear functions, etc., that correlate the data to analyte concentration of another portion of the host, e.g., that convert ISF concentration into the blood concentration; and the like.
In addition, the devices may have a readout means that displays the monitored analyte concentration. Any convenient readout or display means may be employed, including an LCD, etc, where the display means may display the data in any convenient format, e.g., numerically, graphically, etc.
The device and systems may take a variety of different configurations. In certain embodiments, the devices are single, integral devices, in which the measurement means, processing means, display means etc. are all present on the same structure. In yet other embodiments, one or more of the components may be separate from the other components.
s For example, the measurement means may be separated from the display means, where telemetric communication or analysis data transmission means, e.g., radio frequency or RF
means, are employed to provide for data communication between the two or more disparate components of the device.
One representative device embodiment is a "watch" embodiment, in which the device to is configured to be worn around a limbic portion, e.g., a wrist, in a manner analogous to a watch. In this embodiment, all of the components of the device may be present in one integral unit, where the unit is maintained in contact with the skin of the host via an adjustable strap or other retention means. Where the device is to contact a portion of the host that is not readily viewable, e.g., a portion of the waste or other portion that is typically 15 covered by clothes or otherwise not readily viewable, the two component device may be employed, where the measurement means, e.g., sample pads and sensors, are one component of the device and the display or readout means is present on the other component of the device. The two disparate components communicate with each other a data communication means, where the data communication means is typically a wireless data communication 2o means, e.g., RF telemetric means.
UTB.TTY
The subject methods, devices and systems find use in a variety of different applications in which monitoring the concentration of an analyte in a body sample over a 25 given period of time is desired. As such, the subject methods may be employed to: (a) continuously or periodically monitor an analyte whose concentration is associated with a disease condition, e.g., hypo-or hyperglycemia in blood sugar disorders such as diabetes; (b) continuously or periodically monitor an analyte whose concentration is associated with a non-disease physiological condition of interest, e.g., alcohol intoxication, illegal drug use;
30 (c) continuously or periodically monitor the concentration of a therapeutic agent in drug therapy applications; etc.
Where the analyte is glucose, the subject methods find use in a variety of different applications relating to the treatment and management of glucose-associated disease conditions, e.g., diabetes and related conditions. In these embodiments, the subject methods and devices find use in providing for "continual" glucose monitoring, by which is meant that glucose levels in a patient are measured intermittently and automatically according to a predetermined schedule. The subject methods therefore find use in the management of glucose blood levels in glucose metabolism associated disease conditions, by providing for a means to continually monitor the concentration of blood glucose and intervene in an appropriate manner where necessary, e.g., by administration of insulin, by ingestion of sugar, and the like. The subject methods can also be employed to detect and predict the occurrence of hypo- and hyperglycemic conditions. In such applications, the pattern of !o continually monitored analyte concentration measurements can be employed to determine whether a patient is experiencing hyper or hypo glycemia by comparing the pattern to a control or reference pattern. In addition, one can look at a pattern of measurements and compare it to an appropriate control or reference pattern to predict the occurrence of a hypo or hyperglycemic condition. The subject methods can be part of a more comprehensive therapy protocol designed to prevent the occurrence of hypo and hyperglycemic events, e.g., by predicting the occurrence of such events with the subject methods and device and intervening in blood sugar metabolism in a manner that prevents the occurrence of the predicted event, e.g., via insulin injection or glucose ingestion.
The subject methods and devices find use with a variety of different types of hosts 2o where analyte monitoring is desired. Hosts of interest include, but are not limited to mammals. Mammals of interest include valuable livestock, e.g., horses, cows, sheeps, etc., pets, e.g., dogs, cats etc., and humans. In most embodiments, the mammals on which the subject methods are practiced are humans.
KITS
Also provided are kits for practicing the subject methods. In one embodiment, the kits include a device for practicing the subject invention. The device may be a single integral device or made up of two or more disparate components, e.g., a display component and a measurement component. In certain embodiments, the device may be a device in which the 3o measurement means are present on a removable cartridge. In such embodiments, the kits may include a single cartridge, or two or more cartridges. In yet other embodiments, the subject kits may include one or more cartridges for use in a disparate device not included in the kit. Finally, the kits typically include instructions for using the subject reagent test strips in the determination of an analyte concentration in a physiological sample.
These instructions may be present on one or more of the packaging, a label insert, containers present in the kits, and the like.
s The subject methods and devices provide continual measurement of an analyte of interest without the problems experienced with implantable analyte sensors.
For example, because single-use substantially painless analyte measurement means are employed, user irritation and pain are avoided. Furthermore, the individual measurement means employed need not be calibrated prior to use. In addition, with respect to the glucose the subject devices and methods can not only be employed to rapidly and accurately detect the occurrence of a hypo or hyperglycemic event with out host participation, but they can also be employed to readily predict the occurrence of hypo and hyperglycemic conditions, and therefore provide for improved management of blood glucose metabolism associated disease conditions. As such, the subject invention represents a significant contribution to the art.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims (11)
1. A method of monitoring the concentration of an analyte in a host or portion thereof over a given time period, said method comprising:
(a) making a first analyte concentration measurement in said host or portion thereof at a first point in said time period using a first substantially painless single use analyte concentration measurement means;
(b) making a second analyte concentration measurement in said host or portion thereof at a second point in said time period using a second substantially painless single use analyte concentration measurement means; and (c) optionally making one or more additional analyte concentration measurements during said time period using one or more additional substantially painless single use analyte concentration measurement means;
wherein said analyte concentration measurements are made according to a selected scheduling mode to monitor the concentration of said analyze in said host or portion thereof over said given time period.
(a) making a first analyte concentration measurement in said host or portion thereof at a first point in said time period using a first substantially painless single use analyte concentration measurement means;
(b) making a second analyte concentration measurement in said host or portion thereof at a second point in said time period using a second substantially painless single use analyte concentration measurement means; and (c) optionally making one or more additional analyte concentration measurements during said time period using one or more additional substantially painless single use analyte concentration measurement means;
wherein said analyte concentration measurements are made according to a selected scheduling mode to monitor the concentration of said analyze in said host or portion thereof over said given time period.
2. The method according to Claim 1, wherein said analyte measurement concentration measurements are made in situ.
3. The method according to Claim 1, wherein said analyte measurement concentration measurements are made an ex vivo.
4. The method according to Claim 1, wherein the selected scheduling mode comprises a predetermined schedule.
5. A method of monitoring the concentration of glucose in interstitial fluid of a host over a given time period, said method comprising:
(a) making a first interstitial fluid glucose concentration measurement at a first point in said time period using a first substantially painless single use interstitial fluid glucose concentration measurement means;
(b) making a second interestitial fluid glucose concentration measurement at a second point in said time period using a second substantially painless single use interestitial fluid glucose concentration measurement means; and (c) optionally making one or more additional interstitial fluid glucose concentration measurements during said time period using one or more additional substantially painless single use interestitial fluid glucose concentration measurement means;
wherein said interstitial fluid glucose concentration measurements are made according to a predertemined schedule to monitor the concentration of interstitial fluid glucose over said given time period.
(a) making a first interstitial fluid glucose concentration measurement at a first point in said time period using a first substantially painless single use interstitial fluid glucose concentration measurement means;
(b) making a second interestitial fluid glucose concentration measurement at a second point in said time period using a second substantially painless single use interestitial fluid glucose concentration measurement means; and (c) optionally making one or more additional interstitial fluid glucose concentration measurements during said time period using one or more additional substantially painless single use interestitial fluid glucose concentration measurement means;
wherein said interstitial fluid glucose concentration measurements are made according to a predertemined schedule to monitor the concentration of interstitial fluid glucose over said given time period.
6. The method according to Claim 5, wherein said method employs a device that comprises:
(a) at least said first and second substantially painless interstitial fluid glucose measurement means; and (b) an activation means that activates said first and second measurement means according to a predetermined schedule.
(a) at least said first and second substantially painless interstitial fluid glucose measurement means; and (b) an activation means that activates said first and second measurement means according to a predetermined schedule.
7. A device for using in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said device comprising:
(a) at least a first and a second substantially painless single use analyte concentration measurement means; and (b) an activation means for selectively activating said first and second analyte concentration measurement means according to a predetermined schedule.
(a) at least a first and a second substantially painless single use analyte concentration measurement means; and (b) an activation means for selectively activating said first and second analyte concentration measurement means according to a predetermined schedule.
8. The device according to Claim 7, wherein said substantially painless analyte concentration measurement means are interstitial fluid analyte concentration measurement means.
9. The device according to Claim 8, wherein said interstitial fluid analyte concentration measurement means comprise a microneedle.
10. A system for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said system comprising:
(a) a removable cartridge comprising at least a first and a second substantially painless single use analyte concentration measurement means; and (b) a device into which said cartridge may be inserted, wherein said device comprises an activation means for selectively activating said first and second measurement means of said cartridge according to a predetermined schedule.
(a) a removable cartridge comprising at least a first and a second substantially painless single use analyte concentration measurement means; and (b) a device into which said cartridge may be inserted, wherein said device comprises an activation means for selectively activating said first and second measurement means of said cartridge according to a predetermined schedule.
11. A kit for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said kit comprising:
at least one of:
(a) a removable cartridge comprising at least a first and a second substantially painless single use analyte concentration measurement means; and (b) a device into which said cartridge may be inserted, wherein said device comprises a an activation means for selectively activating said first and second measurement means of said cartridge according to a predetermined schedule.
at least one of:
(a) a removable cartridge comprising at least a first and a second substantially painless single use analyte concentration measurement means; and (b) a device into which said cartridge may be inserted, wherein said device comprises a an activation means for selectively activating said first and second measurement means of said cartridge according to a predetermined schedule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/865,826 US6549796B2 (en) | 2001-05-25 | 2001-05-25 | Monitoring analyte concentration using minimally invasive devices |
| US09/865,826 | 2001-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2387287A1 true CA2387287A1 (en) | 2002-11-25 |
Family
ID=25346321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002387287A Abandoned CA2387287A1 (en) | 2001-05-25 | 2002-05-23 | Methods for automatically monitoring analyte concentration using minimally invasive devices |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6549796B2 (en) |
| EP (1) | EP1260815A3 (en) |
| JP (1) | JP2003024284A (en) |
| KR (1) | KR20020090159A (en) |
| CN (1) | CN1388376A (en) |
| AR (1) | AR034330A1 (en) |
| AU (1) | AU785286B2 (en) |
| CA (1) | CA2387287A1 (en) |
| CZ (1) | CZ20021820A3 (en) |
| DZ (1) | DZ3198A1 (en) |
| IL (1) | IL149819A (en) |
| MX (1) | MXPA02005234A (en) |
| PL (1) | PL354134A1 (en) |
| RU (1) | RU2002113638A (en) |
| SG (1) | SG106072A1 (en) |
Families Citing this family (257)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
| US8071384B2 (en) | 1997-12-22 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Control and calibration solutions and methods for their use |
| US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US20050103624A1 (en) * | 1999-10-04 | 2005-05-19 | Bhullar Raghbir S. | Biosensor and method of making |
| US6540675B2 (en) * | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
| US6603987B2 (en) * | 2000-07-11 | 2003-08-05 | Bayer Corporation | Hollow microneedle patch |
| JP4249479B2 (en) * | 2000-09-27 | 2009-04-02 | ギブン イメージング リミテッド | Immobilizable in vivo detection device |
| US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| EP1397068A2 (en) | 2001-04-02 | 2004-03-17 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| US6549796B2 (en) * | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
| AU2002344825A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for improving success rate of blood yield from a fingerstick |
| US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
| WO2002100254A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
| US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
| US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
| CA2448905C (en) | 2001-06-12 | 2010-09-07 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
| US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
| CA2448902C (en) | 2001-06-12 | 2010-09-07 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
| ES2352998T3 (en) | 2001-06-12 | 2011-02-24 | Pelikan Technologies Inc. | LANCETA ELECTRIC ACTUATOR. |
| US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| EP1421775A4 (en) * | 2001-06-28 | 2009-12-23 | Given Imaging Ltd | In vivo imaging device with a small cross sectional area and methods for construction thereof |
| EP1448489B1 (en) * | 2001-11-16 | 2010-08-25 | Stefan Ufer | Flexible sensor and method of fabrication |
| US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
| US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
| US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
| US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
| US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
| US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
| US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
| US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
| US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
| US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
| US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
| US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
| US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US20030216622A1 (en) * | 2002-04-25 | 2003-11-20 | Gavriel Meron | Device and method for orienting a device in vivo |
| US7727181B2 (en) | 2002-10-09 | 2010-06-01 | Abbott Diabetes Care Inc. | Fluid delivery device with autocalibration |
| US7993108B2 (en) | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
| AU2003279237A1 (en) | 2002-10-09 | 2004-05-04 | Therasense, Inc. | Fluid delivery device, system and method |
| JP2006512130A (en) * | 2002-12-26 | 2006-04-13 | ギブン・イメージング・リミテツド | Immobilizable in vivo sensing device |
| US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
| US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| AU2003303597A1 (en) | 2002-12-31 | 2004-07-29 | Therasense, Inc. | Continuous glucose monitoring system and methods of use |
| US7587287B2 (en) | 2003-04-04 | 2009-09-08 | Abbott Diabetes Care Inc. | Method and system for transferring analyte test data |
| US7415299B2 (en) * | 2003-04-18 | 2008-08-19 | The Regents Of The University Of California | Monitoring method and/or apparatus |
| US7679407B2 (en) | 2003-04-28 | 2010-03-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing peak detection circuitry for data communication systems |
| EP2238892A3 (en) | 2003-05-30 | 2011-02-09 | Pelikan Technologies Inc. | Apparatus for body fluid sampling |
| US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
| US20040253736A1 (en) * | 2003-06-06 | 2004-12-16 | Phil Stout | Analytical device with prediction module and related methods |
| US7258673B2 (en) * | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
| US20040249254A1 (en) * | 2003-06-06 | 2004-12-09 | Joel Racchini | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
| US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
| US8058077B2 (en) | 2003-06-20 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Method for coding information on a biosensor test strip |
| US8679853B2 (en) * | 2003-06-20 | 2014-03-25 | Roche Diagnostics Operations, Inc. | Biosensor with laser-sealed capillary space and method of making |
| US8206565B2 (en) | 2003-06-20 | 2012-06-26 | Roche Diagnostics Operation, Inc. | System and method for coding information on a biosensor test strip |
| US7452457B2 (en) | 2003-06-20 | 2008-11-18 | Roche Diagnostics Operations, Inc. | System and method for analyte measurement using dose sufficiency electrodes |
| US8071030B2 (en) | 2003-06-20 | 2011-12-06 | Roche Diagnostics Operations, Inc. | Test strip with flared sample receiving chamber |
| CN1846131B (en) | 2003-06-20 | 2012-01-18 | 霍夫曼-拉罗奇有限公司 | Method and reagent for producing narrow, homogenous reagent strips |
| US7645373B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostic Operations, Inc. | System and method for coding information on a biosensor test strip |
| US8148164B2 (en) | 2003-06-20 | 2012-04-03 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
| US7488601B2 (en) | 2003-06-20 | 2009-02-10 | Roche Diagnostic Operations, Inc. | System and method for determining an abused sensor during analyte measurement |
| US7645421B2 (en) | 2003-06-20 | 2010-01-12 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
| US7718439B2 (en) | 2003-06-20 | 2010-05-18 | Roche Diagnostics Operations, Inc. | System and method for coding information on a biosensor test strip |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| WO2005007223A2 (en) * | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
| US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
| US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
| WO2005037095A1 (en) | 2003-10-14 | 2005-04-28 | Pelikan Technologies, Inc. | Method and apparatus for a variable user interface |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| EP2256493B1 (en) | 2003-12-05 | 2014-02-26 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
| US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
| US20100185071A1 (en) * | 2003-12-05 | 2010-07-22 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
| US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
| US8702597B2 (en) * | 2003-12-31 | 2014-04-22 | Given Imaging Ltd. | Immobilizable in-vivo imager with moveable focusing mechanism |
| JP2007523326A (en) | 2004-02-06 | 2007-08-16 | バイエル・ヘルスケア・エルエルシー | Oxidizable species as internal standards for biosensors and methods of use |
| WO2009048462A1 (en) | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
| WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
| US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
| WO2005119524A2 (en) | 2004-06-04 | 2005-12-15 | Therasense, Inc. | Diabetes care host-client architecture and data management system |
| US7569126B2 (en) | 2004-06-18 | 2009-08-04 | Roche Diagnostics Operations, Inc. | System and method for quality assurance of a biosensor test strip |
| US20060000710A1 (en) | 2004-06-30 | 2006-01-05 | Klaus Peter Weidenhaupt | Fluid handling methods |
| US8170803B2 (en) | 2004-07-13 | 2012-05-01 | Dexcom, Inc. | Transcutaneous analyte sensor |
| CN100459928C (en) * | 2004-11-04 | 2009-02-11 | 株式会社百利达 | Urine sugar meter |
| US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
| US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
| US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
| US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
| WO2006102412A2 (en) | 2005-03-21 | 2006-09-28 | Abbott Diabetes Care, Inc. | Method and system for providing integrated medication infusion and analyte monitoring system |
| CA2605084C (en) * | 2005-04-29 | 2013-11-05 | Norman R. Byrne | Center connect single-sided junction block |
| US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
| US7768408B2 (en) | 2005-05-17 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing data management in data monitoring system |
| US7620437B2 (en) | 2005-06-03 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| ES2717135T3 (en) | 2005-07-20 | 2019-06-19 | Ascensia Diabetes Care Holdings Ag | Method to signal the user to add an additional sample to a test strip, method to measure the temperature of a sample and methods to determine the concentration of an analyte based on controlled amperometry |
| JP2009507224A (en) | 2005-08-31 | 2009-02-19 | ユニヴァーシティー オブ ヴァージニア パテント ファンデーション | Improving the accuracy of continuous glucose sensors |
| CN101273266B (en) | 2005-09-30 | 2012-08-22 | 拜尔健康护理有限责任公司 | Gated voltammetry |
| US8801631B2 (en) | 2005-09-30 | 2014-08-12 | Intuity Medical, Inc. | Devices and methods for facilitating fluid transport |
| US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| CA2624059C (en) | 2005-09-30 | 2019-04-02 | Intuity Medical, Inc. | Multi-site body fluid sampling and analysis cartridge |
| US8423123B2 (en) * | 2005-09-30 | 2013-04-16 | Given Imaging Ltd. | System and method for in-vivo feature detection |
| US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
| US7583190B2 (en) | 2005-10-31 | 2009-09-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing data communication in data monitoring and management systems |
| US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| US8344966B2 (en) | 2006-01-31 | 2013-01-01 | Abbott Diabetes Care Inc. | Method and system for providing a fault tolerant display unit in an electronic device |
| US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
| US20080154107A1 (en) * | 2006-12-20 | 2008-06-26 | Jina Arvind N | Device, systems, methods and tools for continuous glucose monitoring |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
| US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
| US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
| US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
| US20070270651A1 (en) * | 2006-05-19 | 2007-11-22 | Zvika Gilad | Device and method for illuminating an in vivo site |
| US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
| US20080119702A1 (en) * | 2006-10-31 | 2008-05-22 | Abbott Diabetes Care, Inc. | Analyte meter having alert, alarm and test reminder capabilities and methods of use |
| US8579853B2 (en) | 2006-10-31 | 2013-11-12 | Abbott Diabetes Care Inc. | Infusion devices and methods |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| US7713196B2 (en) | 2007-03-09 | 2010-05-11 | Nellcor Puritan Bennett Llc | Method for evaluating skin hydration and fluid compartmentalization |
| US8560059B2 (en) | 2007-03-09 | 2013-10-15 | Covidien Lp | System and methods for optical sensing and drug delivery using microneedles |
| US20080234562A1 (en) * | 2007-03-19 | 2008-09-25 | Jina Arvind N | Continuous analyte monitor with multi-point self-calibration |
| EP2146624B1 (en) | 2007-04-14 | 2020-03-25 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| CA2683962C (en) | 2007-04-14 | 2017-06-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| CA2683930A1 (en) * | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| ES2817503T3 (en) | 2007-04-14 | 2021-04-07 | Abbott Diabetes Care Inc | Procedure and apparatus for providing data processing and control in a medical communication system |
| EP2146623B1 (en) | 2007-04-14 | 2014-01-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| AU2008262018A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| TW200911773A (en) * | 2007-06-12 | 2009-03-16 | Solvay | Epichlorohydrin, manufacturing process and use |
| US20080312518A1 (en) * | 2007-06-14 | 2008-12-18 | Arkal Medical, Inc | On-demand analyte monitor and method of use |
| WO2008157821A1 (en) | 2007-06-21 | 2008-12-24 | Abbott Diabetes Care, Inc. | Health monitor |
| AU2008265541B2 (en) | 2007-06-21 | 2014-07-17 | Abbott Diabetes Care, Inc. | Health management devices and methods |
| US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
| US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
| US20090099427A1 (en) * | 2007-10-12 | 2009-04-16 | Arkal Medical, Inc. | Microneedle array with diverse needle configurations |
| US9131847B2 (en) * | 2007-11-08 | 2015-09-15 | Olympus Corporation | Method and apparatus for detecting abnormal living tissue |
| US9017248B2 (en) * | 2007-11-08 | 2015-04-28 | Olympus Medical Systems Corp. | Capsule blood detection system and method |
| US20100329520A2 (en) * | 2007-11-08 | 2010-12-30 | Olympus Medical Systems Corp. | Method and System for Correlating Image and Tissue Characteristic Data |
| US8162828B2 (en) * | 2007-11-08 | 2012-04-24 | Olympus Medical Systems Corp. | Blood content detecting capsule |
| WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
| US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
| US8252229B2 (en) | 2008-04-10 | 2012-08-28 | Abbott Diabetes Care Inc. | Method and system for sterilizing an analyte sensor |
| US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
| US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
| WO2009145920A1 (en) | 2008-05-30 | 2009-12-03 | Intuity Medical, Inc. | Body fluid sampling device -- sampling site interface |
| US10383556B2 (en) | 2008-06-06 | 2019-08-20 | Intuity Medical, Inc. | Medical diagnostic devices and methods |
| CA2726067C (en) | 2008-06-06 | 2020-10-20 | Intuity Medical, Inc. | Detection meter and mode of operation |
| WO2009155339A1 (en) * | 2008-06-17 | 2009-12-23 | Polymer Technology Systems, Inc. | System and method for packaging dry test strips |
| US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
| US8560082B2 (en) | 2009-01-30 | 2013-10-15 | Abbott Diabetes Care Inc. | Computerized determination of insulin pump therapy parameters using real time and retrospective data processing |
| US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
| WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| WO2010129375A1 (en) | 2009-04-28 | 2010-11-11 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
| US8368556B2 (en) | 2009-04-29 | 2013-02-05 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| US20100299075A1 (en) * | 2009-05-19 | 2010-11-25 | Bayer Healthcare Llc | Systems and methods for calculating an average analyte concentration value |
| US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| US9795326B2 (en) | 2009-07-23 | 2017-10-24 | Abbott Diabetes Care Inc. | Continuous analyte measurement systems and systems and methods for implanting them |
| EP4276652A3 (en) | 2009-07-23 | 2024-01-31 | Abbott Diabetes Care, Inc. | Real time management of data relating to physiological control of glucose levels |
| EP2473963A4 (en) | 2009-08-31 | 2014-01-08 | Abbott Diabetes Care Inc | Medical devices and methods |
| WO2011026147A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
| EP2473099A4 (en) | 2009-08-31 | 2015-01-14 | Abbott Diabetes Care Inc | Analyte monitoring system and methods for managing power and noise |
| US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| EP2506768B1 (en) | 2009-11-30 | 2016-07-06 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
| US9949672B2 (en) | 2009-12-17 | 2018-04-24 | Ascensia Diabetes Care Holdings Ag | Apparatus, systems and methods for determining and displaying pre-event and post-event analyte concentration levels |
| WO2012170000A1 (en) * | 2010-01-22 | 2012-12-13 | Abbott Diabetes Care Inc. | Method, device and system for providing analyte sensor calibration |
| US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
| EP2584964B1 (en) | 2010-06-25 | 2021-08-04 | Intuity Medical, Inc. | Analyte monitoring devices |
| WO2012048168A2 (en) | 2010-10-07 | 2012-04-12 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| CA2827196A1 (en) | 2011-02-28 | 2012-11-15 | Jai Karan | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
| EP4339613A2 (en) | 2011-08-03 | 2024-03-20 | Intuity Medical, Inc. | Body fluid sampling arrangement |
| WO2013049381A1 (en) | 2011-09-28 | 2013-04-04 | Abbott Diabetes Care Inc. | Methods for analyte monitoring management and analyte measurement data management, and articles of manufacture related thereto |
| KR101264610B1 (en) * | 2011-10-24 | 2013-05-27 | 에이케이 글로벌테크 코포레이션 | A Calibrating Breathalyzer |
| WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
| US9069536B2 (en) | 2011-10-31 | 2015-06-30 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
| AU2012335830B2 (en) | 2011-11-07 | 2017-05-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
| US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
| US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
| EP2890297B1 (en) | 2012-08-30 | 2018-04-11 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| WO2014052136A1 (en) | 2012-09-26 | 2014-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
| US9788354B2 (en) | 2013-03-14 | 2017-10-10 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
| US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
| US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
| US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
| JP6076805B2 (en) * | 2013-04-03 | 2017-02-08 | テルモ株式会社 | Component measuring apparatus, method and program |
| US10729386B2 (en) | 2013-06-21 | 2020-08-04 | Intuity Medical, Inc. | Analyte monitoring system with audible feedback |
| AU2014290745A1 (en) | 2013-07-19 | 2015-12-17 | Dexcom, Inc. | Time averaged basal rate optimizer |
| TWI502537B (en) * | 2013-12-13 | 2015-10-01 | Ind Tech Res Inst | Management systems and methods for managing physiology data measurement |
| EP3865063A1 (en) | 2014-03-30 | 2021-08-18 | Abbott Diabetes Care, Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
| JP6681836B2 (en) * | 2014-10-22 | 2020-04-15 | グルタラー メディカル インコーポレイテッド | Continuous blood glucose measuring system and measuring terminal |
| US20160317070A1 (en) * | 2015-04-28 | 2016-11-03 | Ram Sivaraman | Non-invasive blood glucose monitoring with a wearable device |
| JP6461334B2 (en) * | 2015-05-29 | 2019-01-30 | 京セラ株式会社 | Electronics |
| JP6986007B2 (en) | 2015-07-10 | 2021-12-22 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | Systems, devices and methods of dynamic glucose profile response to physiological parameters |
| AU2017245131B2 (en) * | 2016-03-31 | 2020-01-30 | Dexcom, Inc. | Systems and methods for display device and sensor electronics unit communication |
| WO2018100176A1 (en) * | 2016-12-02 | 2018-06-07 | Metemis Development | Cartridge for biochemical sensor |
| EP3600014A4 (en) | 2017-03-21 | 2020-10-21 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
| CN209606445U (en) | 2017-10-24 | 2019-11-08 | 德克斯康公司 | Pre-connection analyte sensor |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11471082B2 (en) * | 2017-12-13 | 2022-10-18 | Medtronic Minimed, Inc. | Complex redundancy in continuous glucose monitoring |
| US11213230B2 (en) | 2017-12-13 | 2022-01-04 | Medtronic Minimed, Inc. | Optional sensor calibration in continuous glucose monitoring |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680628A (en) | 1984-01-04 | 1987-07-14 | Itek Corporation | Realtime digital diagnostic image processing system |
| US4627445A (en) * | 1985-04-08 | 1986-12-09 | Garid, Inc. | Glucose medical monitoring system |
| US4787398A (en) * | 1985-04-08 | 1988-11-29 | Garid, Inc. | Glucose medical monitoring system |
| US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
| US5002054A (en) | 1987-02-25 | 1991-03-26 | Ash Medical Systems, Inc. | Interstitial filtration and collection device and method for long-term monitoring of physiological constituents of the body |
| US5361758A (en) * | 1988-06-09 | 1994-11-08 | Cme Telemetrix Inc. | Method and device for measuring concentration levels of blood constituents non-invasively |
| CA1327838C (en) * | 1988-06-13 | 1994-03-15 | Fred Zacouto | Implantable device to prevent blood clotting disorders |
| US4995402A (en) * | 1988-10-12 | 1991-02-26 | Thorne, Smith, Astill Technologies, Inc. | Medical droplet whole blood and like monitoring |
| US5108819A (en) | 1990-02-14 | 1992-04-28 | Eli Lilly And Company | Thin film electrical component |
| US5161532A (en) | 1990-04-19 | 1992-11-10 | Teknekron Sensor Development Corporation | Integral interstitial fluid sensor |
| DE9113046U1 (en) * | 1991-10-19 | 1991-12-19 | Frese, Volker, 7100 Heilbronn, De | |
| AU4287593A (en) | 1992-04-27 | 1993-11-29 | Avocet Medical, Inc. | Test article and method for performing blood coagulation assays |
| SE500122C2 (en) * | 1992-08-27 | 1994-04-18 | Rudolf Valentin Sillen | Method and apparatus for individually controlled, adaptive medication |
| US5420108A (en) * | 1992-09-14 | 1995-05-30 | Shohet; Isaac H. | Method of controlling diabetes mellitus |
| US6315772B1 (en) * | 1993-09-24 | 2001-11-13 | Transmedica International, Inc. | Laser assisted pharmaceutical delivery and fluid removal |
| GB9223016D0 (en) * | 1992-11-03 | 1992-12-16 | Environmental And Medical Prod | Electrochemical sensor |
| US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
| US5390671A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
| US5582233A (en) * | 1995-02-22 | 1996-12-10 | Noto; Paul V. | Air circulation enhancement system |
| US5879310A (en) | 1995-09-08 | 1999-03-09 | Integ, Inc. | Body fluid sampler |
| US5682233A (en) | 1995-09-08 | 1997-10-28 | Integ, Inc. | Interstitial fluid sampler |
| DE19539194A1 (en) * | 1995-10-20 | 1997-04-24 | Schlattl Werner Bavaria Tech | Method for controlling a welding device and welding device |
| US5879311A (en) * | 1996-05-17 | 1999-03-09 | Mercury Diagnostics, Inc. | Body fluid sampling device and methods of use |
| WO1997042883A1 (en) * | 1996-05-17 | 1997-11-20 | Mercury Diagnostics, Inc. | Disposable element for use in a body fluid sampling device |
| US5823966A (en) * | 1997-05-20 | 1998-10-20 | Buchert; Janusz Michal | Non-invasive continuous blood glucose monitoring |
| US6155992A (en) | 1997-12-02 | 2000-12-05 | Abbott Laboratories | Method and apparatus for obtaining interstitial fluid for diagnostic tests |
| US5971941A (en) * | 1997-12-04 | 1999-10-26 | Hewlett-Packard Company | Integrated system and method for sampling blood and analysis |
| US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| JP2002510515A (en) * | 1998-04-06 | 2002-04-09 | ザ・ジェネラル・ホスピタル・コーポレイション | Non-invasive tissue glucose level monitoring |
| US6505059B1 (en) * | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
| US6086545A (en) | 1998-04-28 | 2000-07-11 | Amira Medical | Methods and apparatus for suctioning and pumping body fluid from an incision |
| US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| DK1077634T3 (en) * | 1998-05-13 | 2003-11-24 | Cygnus Therapeutic Systems | Monitoring of physiological analytes |
| US6302855B1 (en) * | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6368563B1 (en) * | 1999-03-12 | 2002-04-09 | Integ, Inc. | Collection well for body fluid tester |
| US6706159B2 (en) | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
| US6540675B2 (en) | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
| US6549796B2 (en) * | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
-
2001
- 2001-05-25 US US09/865,826 patent/US6549796B2/en not_active Expired - Lifetime
-
2002
- 2002-05-10 AR ARP020101719A patent/AR034330A1/en unknown
- 2002-05-22 DZ DZ020108A patent/DZ3198A1/en active
- 2002-05-23 IL IL149819A patent/IL149819A/en not_active IP Right Cessation
- 2002-05-23 SG SG200203087A patent/SG106072A1/en unknown
- 2002-05-23 CA CA002387287A patent/CA2387287A1/en not_active Abandoned
- 2002-05-24 CZ CZ20021820A patent/CZ20021820A3/en unknown
- 2002-05-24 KR KR1020020028904A patent/KR20020090159A/en not_active Application Discontinuation
- 2002-05-24 RU RU2002113638/15A patent/RU2002113638A/en not_active Application Discontinuation
- 2002-05-24 EP EP02253676A patent/EP1260815A3/en not_active Withdrawn
- 2002-05-24 CN CN02126278A patent/CN1388376A/en active Pending
- 2002-05-24 AU AU44394/02A patent/AU785286B2/en not_active Ceased
- 2002-05-24 MX MXPA02005234A patent/MXPA02005234A/en unknown
- 2002-05-24 JP JP2002151132A patent/JP2003024284A/en not_active Abandoned
- 2002-05-24 PL PL02354134A patent/PL354134A1/en not_active Application Discontinuation
-
2003
- 2003-03-03 US US10/379,463 patent/US6738654B2/en not_active Expired - Lifetime
-
2004
- 2004-02-18 US US10/782,271 patent/US20040162473A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030158472A1 (en) | 2003-08-21 |
| RU2002113638A (en) | 2004-01-27 |
| JP2003024284A (en) | 2003-01-28 |
| US6549796B2 (en) | 2003-04-15 |
| US6738654B2 (en) | 2004-05-18 |
| AR034330A1 (en) | 2004-02-18 |
| IL149819A0 (en) | 2002-11-10 |
| IL149819A (en) | 2006-08-20 |
| AU785286B2 (en) | 2006-12-21 |
| DZ3198A1 (en) | 2005-02-20 |
| SG106072A1 (en) | 2004-09-30 |
| MXPA02005234A (en) | 2003-10-06 |
| CN1388376A (en) | 2003-01-01 |
| EP1260815A3 (en) | 2005-03-23 |
| EP1260815A2 (en) | 2002-11-27 |
| US20040162473A1 (en) | 2004-08-19 |
| PL354134A1 (en) | 2002-12-02 |
| KR20020090159A (en) | 2002-11-30 |
| CZ20021820A3 (en) | 2003-04-16 |
| US20020177764A1 (en) | 2002-11-28 |
| AU4439402A (en) | 2002-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6738654B2 (en) | Methods for automatically monitoring analyte concentration using minimally invasive devices | |
| US20230066611A1 (en) | Calibration of analyte measurement system | |
| US7343188B2 (en) | Devices and methods for accessing and analyzing physiological fluid | |
| Thennadil et al. | Comparison of glucose concentration in interstitial fluid, and capillary and venous blood during rapid changes in blood glucose levels | |
| Ginsberg | An overview of minimally invasive technologies | |
| US7258673B2 (en) | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein | |
| US20040138539A1 (en) | Non-invasive blood monitor | |
| Gebhart et al. | Glucose sensing in transdermal body fluid collected under continuous vacuum pressure via micropores in the stratum corneum | |
| JP2004510453A5 (en) | ||
| JP2013009992A (en) | System and method for continuous analyte monitoring | |
| WO2002100278A1 (en) | Sampling devices and methods utilizing a horizontal capillary test strip | |
| EP1196078A1 (en) | Reusable analyte sensor site | |
| EP1399066B1 (en) | Devices for the expression of bodily fluids from an incision | |
| EP0236023A2 (en) | Non-invasive blood glucose level monitoring method | |
| EP2425770A1 (en) | Implantable device for real-time monitoring of glycemia and dosage | |
| Thorsell et al. | Continuous glucose monitoring: a stepping stone in the journey towards a cure for diabetes | |
| US20120059236A1 (en) | Implantable device for real-time monitoring of glycemia and dosage | |
| Goez-Mora et al. | Improving real-time and remote monitoring system for diabetic subjects using flash continuous glucose measurement: accuracy and reliability | |
| OPARAJI | NON-INVASIVE BLOOD GLUCOSE MONITORING: A NEW APPROACH FOR DIABETIC PATIENTS | |
| TR2022018633A2 (en) | SMART FOOT WEAR THAT CAN MEASURE SUGAR AND TEMPERATURE | |
| Behrend | Home monitoring of diabetic patients. | |
| Bansod et al. | Comparative study of current approaches for minimally invasive and non-invasive blood glucose monitoring | |
| Bode et al. | PUBLISHED ONLY: CLINICAL THERAPEUTICS/NEW TECHNOLOGY-GLUCOSE MONITORING AND SENSING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |